» Articles » PMID: 38003876

Neuropsychiatric Manifestations of Mast Cell Activation Syndrome and Response to Mast-Cell-Directed Treatment: A Case Series

Overview
Journal J Pers Med
Date 2023 Nov 25
PMID 38003876
Authors
Affiliations
Soon will be listed here.
Abstract

Mast cell activation syndrome (MCAS) is an immune disease with an estimated prevalence of 17%. Mast cell chemical mediators lead to heterogeneous multisystemic inflammatory and allergic manifestations. This syndrome is associated with various neurologic and psychiatric disorders, including headache, dysautonomia, depression, generalized anxiety disorder, and many others. Although MCAS is common, it is rarely recognized, and thus, patients can suffer for decades. The syndrome is caused by aberrant mast cell reactivity due to the mutation of the controller gene. A case series is presented herein including eight patients with significant neuropsychiatric disorders that were often refractory to standard medical therapeutics. Five patients had depression, five had generalized anxiety disorder, and four had panic disorder. Other psychiatric disorders included attention-deficit hyperactivity disorder, obsessive compulsive disorder, phobias, and bipolar disorder. All eight patients were subsequently diagnosed with mast cell activation syndrome; six had comorbid autonomic disorders, the most common being postural orthostatic tachycardia syndrome; and four had hypermobile Ehlers-Danlos syndrome. All patients experienced significant improvements regarding neuropsychiatric and multisystemic symptoms after mast-cell-directed therapy. In neuropsychiatric patients who have systemic symptoms and syndromes, it is important to consider the presence of an underlying or comorbid MCAS.

Citing Articles

Neurodivergence, intersectionality, and eating disorders: a lived experience-led narrative review.

Cobbaert L, Millichamp A, Elwyn R, Silverstein S, Schweizer K, Thomas E J Eat Disord. 2024; 12(1):187.

PMID: 39568093 PMC: 11580580. DOI: 10.1186/s40337-024-01126-5.


Mast cell activation syndrome: An up-to-date review of literature.

Ozdemir O, Kasimoglu G, Bak A, Sutluoglu H, Savasan S World J Clin Pediatr. 2024; 13(2):92813.

PMID: 38948000 PMC: 11212760. DOI: 10.5409/wjcp.v13.i2.92813.

References
1.
Kempuraj D, Selvakumar G, Thangavel R, Ahmed M, Zaheer S, Raikwar S . Mast Cell Activation in Brain Injury, Stress, and Post-traumatic Stress Disorder and Alzheimer's Disease Pathogenesis. Front Neurosci. 2018; 11:703. PMC: 5733004. DOI: 10.3389/fnins.2017.00703. View

2.
Weinstock L, Walters A, Brook J, Kaleem Z, Afrin L, Molderings G . Restless legs syndrome is associated with mast cell activation syndrome. J Clin Sleep Med. 2020; 16(3):401-408. PMC: 7075100. DOI: 10.5664/jcsm.8216. View

3.
Afrin L, Pohlau D, Raithel M, Haenisch B, Dumoulin F, Homann J . Mast cell activation disease: An underappreciated cause of neurologic and psychiatric symptoms and diseases. Brain Behav Immun. 2015; 50:314-321. DOI: 10.1016/j.bbi.2015.07.002. View

4.
Jendoubi F, Severino-Freire M, Negretto M, Arbus C, Paul C, Livideanu C . Neuropsychiatric, cognitive and sexual impairment in mastocytosis patients. Orphanet J Rare Dis. 2021; 16(1):118. PMC: 7934538. DOI: 10.1186/s13023-021-01747-y. View

5.
Haenisch B, Molderings G . White matter abnormalities are also repeatedly present in patients with systemic mast cell activation syndrome. Transl Psychiatry. 2018; 8(1):95. PMC: 5943358. DOI: 10.1038/s41398-018-0143-5. View